Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Allen, Marianne P. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S866000, C514S903000, C514S002600
Reexamination Certificate
active
06933276
ABSTRACT:
The present invention relates to neurotrophin-3 (NT-3), a newly discovered member of the BDNF gene family. It is based, in part, on the identification of regions of nucleic acid sequence homology shared by BDNF and NGF (U.S. patent application Ser. No. 07/400,591, filed Aug. 30, 1989, incorporated by reference herein). According to the present invention, these regions of homology may be used to identify new members of the BDNF/NGF gene family; such methodology was used to identify NT-3. The present invention provides for the genes and gene products of new BDNF/NGF related neurotrophic factors identified by these methods. According to the invention, NT-3 may be used in the diagnosis and/or treatment of neurologic disorders, including, but not limited to, Alzheimer's disease and Parkinson's disease. Because NT-3 has been observed to exhibit a spectrum of activity different from the spcificities of BDNF or NGF, NT-3 provides new and valuable options for enducing regrowth and repair in the central nervous system.
REFERENCES:
patent: 4414150 (1983-11-01), Goeddel
patent: 4699875 (1987-10-01), Appel
patent: 5169764 (1992-12-01), Shooter et al.
patent: 5180820 (1993-01-01), Barde et al.
patent: 0 121 338 (1984-10-01), None
patent: 0 386 752 (1990-12-01), None
patent: 1-58983 (1989-03-01), None
patent: 1-127710 (1989-05-01), None
patent: 1-193654 (1989-07-01), None
patent: 1-263613 (1989-10-01), None
Chaudry et al., Muscle Nerve, 23(2):189-92, 2000.
Apfel, Clinical Chemistry and Laboratory Medicine, 39(4):351-355, 2001.
Apfel, American Journal of Medicine, 107(2B):34S-42S.
Barinaga, M.,Science, 264:772-774, 1994.
Kanje et al. Brain Research486:396-398 (1989).
Ullrich et al., “Human β-nerve growth factor gene sequence highly homologous to that of mouse,” 1983,Nature 303:821-5.
Scott et al., “Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor.” 1983,Nature 302:538-40.
Liebrock et al., “Molecular cloning and expression of brain derived neurotrophic factor.”, 1989,Nature 341:149-52.
Lindsay and Peters, “Spinal cord contains neurotrophic activity for spinal nerve sensory neurons. Late developmental appearance of a survival factor distinct from nerve growth factor.”, 1984,Neurosci. 12:45-51.
Lindsay and Rohrer, “Placodal sensory neurons in culture. Nodose ganglion neurons are unresponsive to NGF, lack NGF receptors, but are supported by a liver-derived neurotrophic factor.”, 1985,Develop. Biol. 112:30-48.
Edwards et al., “Processing of the native nerve growth factor precursor to form biologicaly active nerve growth factor.”, 1988,J. Biol. Chem. 263:6810-6815.
Edwards et al., “Processing and secretion of nerve growth factor: Expression in mammalian cells with a vaccinia virus vector.”, 1988,Mol. Cell. Biol. 8:2456-64.
Selby et al., “Cobra nerve growth factor: Structure and evolutionary comparison.”, 1987,J. Neurosci. Res. 18:293-8.
Davies et al., “Different factors from the central nervous systems and periphery regulate the survival of sensory neurons.”, 1986,Nature, 319:497-499.
Aruffo & Seed, “Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.”, 1987,Proc. Natl. Acad. Sci. USA, 84:8573-8577.
Radeke et al., “Gene transfer and molecular cloning of the rat nerve growth factor receptor.”, 1987,Nature, 325:593-597.
Altman, “Autoradiographic and Histological Studies of Postnatal Neurogenesis,” 1966,J. Comp. Neur., 128:431-474.
Schlesinger et al. “An Autoradiographic Study of the Time of Origin and the Pattern of Granule Cell Migration in the Dantate Gyrus of the Rat.”, 1975,J. Comp. Neur., 159:149-176.
Large et al., “Nerve Growth Factor Gene Expression in the Developing Rat Brain.”, 1986,Science 234:352-355.
Koh and Loy, “Localization and Development of Nerve Growth Factor-Sensitive Rat Basal Forebrain Neurons and Their Afferent Projections to Hippocampus and Neocortex.”, 1989,J. Neurosci. 9:2999-3018.
Ernfors et al. “Expression of Nerve Growth Factor Receptor mRNA is Developmentally Regulated and Increased after Axotomy in Rat Spinal Cord Motoneurons.”, 1989,Neuron 2:1605-1613.
Clegg et al., “Regulation of Nerve Growth Factor mRNA Levels in Developing Rat Heart Ventricle is Not Altered by Sympathectomy.”, 1989,Dev. Biol. 13430-37.
Darling et al., “The Biosynthesis and Processing of Proteins in the Mouse 7S Nerve Growth Factor Complex.”, 1983,Cold Spring Harbor Symp. Quant. Biol. 1:427-34.
Kaisho et al., “Cloning and expression of a cDNA encoding a novel human neurotrophic factor.”, Jun. 1990,FEBSLetters 266(1,2):187-191.
Rosenthal et al. “Primary structure and biological activity of a novel human neurotrophic factor.”, May 1990,Neuron 4:767-773.
Hu, G.L. et al., “Expression of the DNA for mouse β-nerve growth factor protein inEscherichia coli.” 1988,Gene 70:57-65.
Appel, S.H. et al., “Neuropeptides and Alzheimer's disease: potential role of neurotrophic factors.”, 1985,Chemical Abstracts 102:401, abstract No. 43871b.
Appel, S.H. et al., “New approaches to Alzheimer's disease: Neurotrophic factors.”, 1985,Chemical Abstracts 102:418, abstract No. 147008s.
Uchida, Y. et al., “Neurotrophic factors in Alzheimer's disease brain.”, 1989,Chemical Abstracts 111:203, abstract No. 229882X. Abstract of a review article:Shinkei Seishiu Yakuri, 1989 11(8), 633-9 (not in possession of Applicants). See also, enclosedMedlineprintout showing abstracts discussing this author's hypothesis.
Hallböök et al., “Production and characterization of Biologically Active Recombinant Beta Nerve Growth Factor.”, Jan. 1988,Molecular and Cellular Biology, 8(1):452-456.
Erlich, H. et al., “Specific DNA Amplification.”, Feb. 1988,Nature 331:461-462.
Pauli, U. et al., “Porcine tumor necrosis factor alpha: cloning with the polymerase chain reaction and determination of the nucleotide sequence.”, Sep. 1989,Gene 81: 185-191.
Finn Hallböök, Carlos F. Ibá{overscore (n)}ez and Häkan Persson, 1991, “Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abuntdantly Expressed in Xenopus Ovary” Neuron 6:845-858.
Nancy Y. Ip, Carlos F. Ibá{overscore (n)}ez, Steven H. Nye, Joyce McClain, Pamela F. Jones, David R. Gies, Leonardo Belluscio, Michelle M. Le Beau, Rafael Espinosa III, Stephen P. Squinto, Häkan Persson and George D. Yancopoulos “Mammalian neurotrophin-4: Structure, chromosomal localization, tissue distribution, and receptor specificity.” Proc. Natl. Acad. Sci. USA 89:3060-3064.
Lucy R. Berkemeier, John W. Winslow, David R. Kaplan, Karoly Nikolics, David V. Goeddel and Arnon Rosenthal “Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB” Nov., 1991, Neuron 7(5):857-866.
Geoffrey M. Wahl, Shelby L. Berger, and Alan R. Kimmel, 1987, “Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations” Chapter 43, Methods in Enzymology, vol. 152,Guide to Molecular Cloning Techniques, Ed. Shelby L. Berger and Lan R. Kimmel.
R. Bruce Wallace and C. Garrett Miyada, 1987, “Oligonucleotide Probes for the Screening of Recombinant DNA Libraries” Chapter 43, Methods in Enzymology, vol. 152,Guide to Molecular Cloning Techniques, Ed. Shelby L. Berger and Lan R. Kimmel.
Maisonpierre et al., “Human and Rat Brain-Derived Neurotrophin Factor and Neurotrophin-3: Gene Structures, Distributions, and Chromosomal Localizations”, Genomics 10:558-568 (1991).
Hohn et al., Nature 344:339-341 (1990).
Maisonpierre et al., Science 247:1446-1451 (1990).
Klein et al., trkB, a Novel Tyrosine Protein Kinase Receptor Expressed During Mouse Neural Development, EMBO J. 8(12):3701-3709 (1989).
Klein et al.,
Barde Yves-Alain
Hohn Andreas
Lindsay Ronald M.
Thoenen Hans
Yancopoulos George
Allen Marianne P.
Gregg, Esq. Valeta
Regeneron Pharmaceuticals Inc.
LandOfFree
Methods of treating peripheral neuropathies using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating peripheral neuropathies using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating peripheral neuropathies using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523903